42 results about "Diabetic wound healing" patented technology

The invention provides compositions and methods useful for treating wounds and enhancing wound healing, particularly for diabetic wound healing.

A method for treating diabetic complications by administration of a beta-blocker is disclosed. Diabetic complications arise from diabetes and have few or no existing treatment options. The present invention describes the use of a beta-blocker in the treatment of a diabetic. The present invention also describes the inhibition of aldose reductase, one of the chief causative factors of diabetic complications. Also provided are methods of diabetic wound healing. Compositions for treating diabetic complications, such as diabetic wounds, are disclosed. The present invention includes employing a topical formulation of a beta-blocker, having substantially no antibacterial activity, to improve the process of diabetic wound healing. The present invention also involves increasing the rate of collagen accumulation of the healing epithelialized tissue in the wound of a diabetic individual.

The invention discloses an application of ocean collagen peptide in the process of preparing diabetes wound healing medicaments and foods. The ocean collagen peptide has the characteristics of easiness and quickness in absorption, low viscosity, good water solubility and the like. The diabetes wound healing degree, the granulation tissue formation, the collagenous fiber deposition and the blood vessel formation can be improved by taking the ocean collagen peptide; and the ocean collagen peptide has the function of promoting the diabetes wound healing. When being applied into the preparation of the medicaments and the foods for promoting the diabetes wound healing, the ocean collagen peptide has important scientific value and economic benefit, thereby providing a new way for the promotion of the diabetes wound healing through diet.

Disclosed are a method and a composition for the prevention or treatment of diabetic angiogenesis impairment or diabetic wound-healing impairment, using C-peptide. Found to be able to induce angiogenesis through chemotatic migration of endothelial cells, cell migration to wounded areas, capillary-like network formation, and ERK1 / 2 and Akt phosphorylation and NO production, C-peptide has prophylactic or therapeutic applications in a broad spectrum of various diabetic complications including diabetic angiogenesis impairment.

The invention discloses an emodin succinyl ester type compound as well as a preparation method and application thereof. The compound disclosed by the invention has a structure shown as a formula I (wherein, R is C1 to C5 alkyl); preferably, the compound is emodin succinyl ethyl ester. An experiment proves that the emodin succinyl ester type compound disclosed by the invention can be used for promoting the healing of diabetes mellitus wounds better when being compared with emodin, and can be used for preparing a medicine for promoting the healing of the diabetes mellitus wounds. Furthermore, the invention further discloses a method for preparing the compound; the method has a simple route, can effectively shorten the synthesis time and reduce the cost, is simple to operate and easy to implement, so that the method is suitable for industrial production. (The formula I is shown in the description.).

The invention relates to the technical field of biomedical materials, in particular to a cascade enzyme-like nano system for promoting healing of diabetic wounds and a preparation method and application thereof. The nano system comprises metal oxide nano particles and glucose oxidase modified on the surface of metal oxide. Glucose oxidase is modified on the surfaces of metal oxide nano-particles to obtain a cascade enzyme-like nano material which is used for regulating the micro-environment of the diabetic infected wounds and promoting the wounds to heal quickly.

The invention provides a preparation method of nano-composite hydrogel and application of the nano-composite hydrogel in promoting healing of diabetic wounds. The method comprises the following steps: preparing a functionally modified natural high-molecular polymer and functional metal oxide nanoparticles, mixing the functionally modified natural high-molecular polymer solution with the functional metal oxide nanoparticles, and finally preparing the nano composite hydrogel by means of enzymatic crosslinking and photo-crosslinking. The hydrogel prepared by the method has multiple functions, and can be used for adjusting the pathological microenvironment of the diabetic wound to promote the healing of the diabetic wound.

The invention relates to hydrogel capable of releasing metformin with pH / glucose dual responsiveness and a preparation method and application of the hydrogel. The preparation method comprises the following steps: adding polydopamine-coated reduced graphene oxide (rGO (at) PDA) and metformin (Met) into a benzaldehyde and phenylboronic acid dual-modified polyethylene glycol copolymer (PPB) solution at the same time; and then mixing with a dihydrocaffeic acid and L-arginine co-grafted chitosan (CDL) solution, and carrying out crosslinking through Schiff base and phenyl borate to form the pH / glucose dual-responsive PC / GO / Met hydrogel. The method is wide in raw material source, simple in preparation process and low in preparation cost, and the prepared hydrogel dressing has double responsiveness, can release drugs beneficial to wound healing of type II diabetes mellitus and promote wound healing of diabetes mellitus, has the characteristic of pH / glucose double-responsiveness metformin release, and can be applied to the field of wound healing of type II diabetes mellitus and wound healing of type II diabetes mellitus. And good adhesion, antibacterial property, oxidation resistance, blood coagulation and in-vivo hemostasis capability are realized.

The invention provides a traditional Chinese medicine composition for promoting healing of diabetic wounds. The composition is prepared by the following raw materials in parts by weight: 8-16 parts of notoginseng, 38-46 parts of scutellaria roots, 0.1-2 parts of borneol, and 0.1-0.5 parts of aquilaria wood essential oil. A preparation method comprises the following steps: 1. notoginseng and scutellaria roots are weighed in proportion, drying and crushing are carried out, and the materials are sieved by a 200 mesh sieve; 2. notoginseng powder and scutellaria roots are added into distilled water, immersion is carried out for 0.5 hours, ultrasonic treatment is carried out at 50 DEG C for 1 hour, and filtering is carried out; filter residues are added into ethanol whose concentration is 50% according to a proportion 1:10, ultrasonic treatment is carried out for 30 minutes, filtering and combination of filtrate are carried out, the filtrate is added into a rotary evaporator for condensation, and freeze drying is carried out; 3. according to a proportion, the aquilaria wood essential oil is diluted in 50 parts of a physiological saline solution of 5% propylene glycol; 4. according to a proportion, the borneol is added into an extract product, the solution of aquilaria wood is added according to a proportion, and after uniform stirring, the traditional Chinese medicine composition paste agent is obtained. The traditional Chinese medicine composition can accelerate healing of wounds of rats with diabetes.

The invention discloses firstly non-coding RNA for treating delayed healing of diabetic wounds and diabetes-related complications and application of the non-coding RNA. Upon animal experiments, the non-coding RNA disclosed by the invention is proved to be effective on promoting healing of diabetic wounds, and the non-coding RNA is of great significance for the treatment of delayed healing of wounds in patients of diabetes and for the treatment of ulcer, erosion, gangrene and diabetic foot caused by the diabetes.

The present invention relates to a novel alkaloid and novel bioactive alkaloid fractions derivable from Ribes preferably selected among Ribes Rubrum and Ribes nigrum; methods of manufacturing such bioactive Ribes alkaloid fractions and their use for the inhibition of IKK-β, PDE4 and / or PDE5 and in addition their promoting effect on mitochondrial biogenesis and function; their therapeutic or non-therapeutic applications as nutritive or medicinal products in the management of conditions associated with impaired mitochondrial function or IKK-β, PDE4 and / or PDE5 activity, such as inflammation, neurodegeneration, dyslipidemia, type 2 diabetes mellitus, impaired wound healing, sarcopenia and other conditions associated with muscle dysfunction or tiredness and fatigue, or where optimization of muscular or cognitive function is desired; extracts, juices or concentrates of Ribes comprising such alkaloids; compostions comprising such alkaloids, including pharmaceutical compositions, nutritive product such as functional foods and nutraceutical compositions, and cosmetic compositions and medical devices.

The invention discloses use of growth differentiation factor 11 in promoting healing of a diabetic wound and belongs to the technical field of medicine. By establishing a Type-I diabetic mouse wound model induced with streptozotocin (STZ) of effective concentration, the influence of the growth differentiation factor 11 upon the healing of the diabetic mouse wound model is estimated, the study discovers that the growth differentiation factor 11 can accelerate the healing of the diabetic mouse wound, and the healing speed of the wound is higher than that of both a positive control group (EGF) and a blank control group. Therefore, an effective technical means to heal and treat diabetic wounds is provided herein.

The invention relates to an application of Lycogen in preparing a Lycogen composition for promoting diabetes wound healing, and the Lycogen composition comprises an effective amount of a Lycogen extract. The invention also relates to an application of Lycogen in preparing a Lycogen composition for inhibiting cancer metastasis in an adjunctive manner, and the Lycogen composition comprises an effective amount of a Lycogen extract. The Lycogen extract comprises active ingredients selected from [zeta]-carotene, neurosporene, spheroidenone and / or methoxyneurosporene.

The present invention is related to a method for diabetic wound healing comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably salsolinol.

The invention belongs to the field of medicines, and relates to an application of geranyl flavone A in preparation of medicines for promoting wound healing. Specifically, the invention relates to an application of geranyl flavone A in preparation of medicines for promoting wound healing of type II diabetes mellitus. The geranyl flavone A can effectively promote wound healing and has a potential ofbeing used for preparing medicines for promoting wound healing, especially preventing and treating diabetic feet.

The invention discloses a diabetic wound healing agent and application thereof. The healing agent is acidic electrolyzed water with an OPR value greater than 1,100 mV. By physical principles, the diabetic wound healing agent provided by the invention can be used to quickly and effectively form a sterile environment for the wound and around the wound; by high potential of the agent itself, nerve cells are activated and human immunity and self-repairing ability are enhanced to achieve rapid healing of wounds. The healing agent is suitable for disinfection of various wounds caused by trauma, burns and other unhealed wounds. The healing agent can not only clean the wound, but also sterilize and disinfect. In addition, the healing agent also has efficacy of promoting cell tissue regeneration, and has excellent effects of stopping bleeding and pain, diminishing inflammation and eliminating swelling. By the use of the healing agent, the wound is healed quickly.

The present invention is related to a method for diabetic wound healing comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably salsolinol.

The invention discloses a medicine for treating diabetic ulcer. The medicine is gel consisting of solute, cinnamyl aldehyde, a solvent and PEG 400 (Polyethylenglycol 400), wherein the concentration of the cinnamyl aldehyde in the gel is 1.2-20mu mol / L. The medicine for treating diabetic ulcer is at a gel state, is smeared at wounds when being used, is capable of remarkably improving diabetic wound healing, and is good in treatment effect and safe and convenient to use.

The invention provides an application of melatonin and mecobalamin in treatment of diabetic wound healing disorders, and belongs to the technical field of biological medicine. Research of the invention shows that the combined use of the melatonin and the mecobalamin can significantly promote healing of wound surfaces of diabetic rats, and the effect of the combined medication is better than that of the melatonin when used alone; the combined medication significantly promotes the healing of diabetic skin wounds by reducing inflammatory response at the wound part and increasing the number of epidermal stem cells; and a current status of diabetic wound treatment (difficult to heal and high costs of treatment) and the advantages of price and application safety of small molecule drugs such as the melatonin and the mecobalamin are combined, the research of the mixed preparation of the melatonin and the mecobalamin has important clinical practical value, and the research results of the invention provide a theoretical basis and novel treatment ideas for clinical application.

The invention discloses novel application of a FoxO1 selective inhibitor AS1842856. The novel application of a compound shown in a formula I is the application in the preparation of medicaments for the prevention and / or treatment of wound healing disorder, especially in the preparation of medicaments for diabetic wound healing disorders. Pharmacodynamics experiments confirm that AS1842856 can significantly promote wound healing of diabetic mice. The invention has good application prospect in the treatment of diabetic wound healing disorder.

Diabetes wounds have extremely complex hyperglycemia, hypoxia and high reactive oxygen species (ROS) microenvironments. Consequently, modulation and management of this microenvironment may provide an updated and improved treatment approach for healing of diabetic wounds. In this case, we develop a multifunctional nano-enzyme (CHA at GOx) for diabetes wound treatment, which is jointly assembled based on special dual ligands (alendronate and dimethylimidazole) driven by Ce and glucose oxidase (GOx). According to the present invention, the activity of GOx is protected, and the simulation activity of superoxide dismutase (SOD) and catalase (CAT) is provided, such that the excess glucose and ROS can be effectively removed; particularly, excessive hydrogen peroxide (H2O2) generated by glucose oxidation reaction can be catalyzed to generate oxygen, so that the oxygen balance of the wound surface is adjusted, and the toxic and side effects of GOx are reduced. In addition, the cerium nano-composite also has the effects of promoting cell proliferation and migration and promoting angiogenesis. In-vitro experiments show that CHA (at) GOx contributes to cell migration and promotes formation of cell tubes. In vivo, wound healing of diabetic mice can be obviously accelerated. In a word, the research shows that co-assembly of the multifunctional nano-enzyme has potential in clinical treatment of diabetic wounds.

The invention provides a repairing agent for promoting wound healing of type 2 diabetes, and belongs to the technical field of diabetes. The repairing agent provided by the invention is composed of a low-concentration NPY solution and adipose-derived stem cells. By using the repairing agent provided by the invention, wounds of type 2 diabetes mice can be quickly and efficiently repaired. In addition, the repairing agent provided by the invention can effectively promote hair follicle generation and hair follicle growth at the wound, can effectively inhibit expression of pro-inflammatory genes IL-1 and TNF-alpha, and can promote expression of anti-inflammatory genes VEGF and TGF-beta.

The invention provides compounds, compositions, and methods to improve or accelerate the healing of a wound. In various embodiments, the methods can include the topical treatment of the wound with the enzyme MMP-8, or the topical treatment of the wound with MMP-8 in combination with administration of an MMP-9 inhibitor, to accelerate the healing of the wound.

The invention discloses an emodin succinyl ester type compound as well as a preparation method and application thereof. The compound disclosed by the invention has a structure shown as a formula I (wherein, R is C1 to C5 alkyl); preferably, the compound is emodin succinyl ethyl ester. An experiment proves that the emodin succinyl ester type compound disclosed by the invention can be used for promoting the healing of diabetes mellitus wounds better when being compared with emodin, and can be used for preparing a medicine for promoting the healing of the diabetes mellitus wounds. Furthermore, the invention further discloses a method for preparing the compound; the method has a simple route, can effectively shorten the synthesis time and reduce the cost, is simple to operate and easy to implement, so that the method is suitable for industrial production. (The formula I is shown in the description.).

The invention discloses use of growth differentiation factor 11 in promoting healing of a diabetic wound and belongs to the technical field of medicine. By establishing a Type-I diabetic mouse wound model induced with streptozotocin (STZ) of effective concentration, the influence of the growth differentiation factor 11 upon the healing of the diabetic mouse wound model is estimated, the study discovers that the growth differentiation factor 11 can accelerate the healing of the diabetic mouse wound, and the healing speed of the wound is higher than that of both a positive control group (EGF) and a blank control group. Therefore, an effective technical means to heal and treat diabetic wounds is provided herein.

The invention relates to a chronic wound healing composition and application thereof, in particular to a composition with a chronic wound healing effect, especially a composition with a diabetic wound healing effect. The composition mainly comprises the following three components: (1) an anti-inflammatory agent selected from a group consisting of acteoside, isoacteoside and a combination of the acteoside and the isoacteoside; (2) an astringent selected from a group consisting of gallic acid, subgallic acid, salts thereof and a combination of the gallic acid, the subgallic acid and the salts; and (3) a freshener selected from a group consisting of borneol, menthol and a combination of the borneol and the menthol, and optionally combined with one or more pharmaceutically acceptable carriers as needed. The invention also provides application of the composition to preparation of a medicament for treating chronic wounds, especially diabetic wounds.

The invention provides compounds, compositions, and methods to improve or accelerate the healing of a wound. In various embodiments, the methods can include the topical treatment of the wound with the enzyme MMP-8, or the topical treatment of the wound with MMP-8 in combination with administration of an MMP-9 inhibitor, to accelerate the healing of the wound.